



Hospital-Based Prevalence of Diabetic Retinopathy and Clinical Correlates among Diabetics Attending a Tertiary Eye Clinic in Makurdi Central Nigeria

Tongriang J. Ben-Ameh¹, Chaha Kator¹, McAnthony Ben-Ameh², Ugochukwu A. Eze^{3,4,5}

¹Department of Ophthalmology, Faculty of Clinical Sciences, College of Health Sciences, Father Moses Orshio Adasu University (formerly Benue State University)/ Benue State University Teaching Hospital Makurdi, Nigeria

²Department of Family Medicine, Federal Medical Centre, Makurdi, Nigeria

³Department of Ophthalmology, Federal Medical Centre, Asaba, Nigeria

⁴Cephas Research Initiative Inc. Ibadan

⁵Department of Research, University of Puthisastra, Phnom-Penh, Cambodia

Abstract

Context: Diabetic retinopathy (DR) is the most common ocular complication seen in patients with diabetes mellitus. Periodic screening for DR in diabetics is recommended.

Objective: To determine the prevalence of diabetic retinopathy (DR) and clinical correlates of diabetic patients receiving care at the Benue State University Teaching Hospital (BSUTH), Makurdi, following screening for diabetic retinopathy.

Materials and Methods: A hospital-based analytic cross-sectional study was carried out among diabetic patients attending the endocrinology and general outpatient clinics at the BSUTH. Data was obtained using an interviewer-administered questionnaire. A comprehensive eye examination was conducted for all the participants. Descriptive analysis (frequencies and percentages for categorical data and mean with standard deviation for quantitative data) was done. The chi-square test and logistic regression were used to test the association between the outcome variable and independent variables at a level of significance of $p < 0.05$.

Results: A total of 371 patients with an age range of 23-76 years (mean age 54.4 ± 11.6 years) were enrolled in the study. Majority (215, 58.0%) were females. About 144 (38.8%) of the patients had diabetic retinopathy. Macular oedema was detected in 64 (44.4%) of participants. The predictors of DR were duration of diabetes mellitus ($AOR=1.29, p<0.001$) poor glycaemic control with average FBS ≥ 7.0 mmol/L ($AOR=2.87, P<0.001$), systolic hypertension ($AOR=2.31, P=0.001$) and renal disease ($AOR=3.27, P<0.001$).

Conclusion: The hospital-based prevalence of DR in this study was high at 38.8% and the predictors of DR were duration of diabetes, poor glycaemic control, systemic hypertension and renal disease. Routine screening of diabetic patients (especially those with a longer history of DM) and early treatment of DR will reduce the risk of developing sight-threatening DR and blindness.

Keywords – Prevalence, Diabetic retinopathy, clinical correlates, Nigeria.

Corresponding Author:

Dr. Ugochukwu Anthony Eze

Department of Research, University of Puthisastra, Phnom-Penh, Cambodia

ugorexeze@gmail.com

DOI: 10.61386/imj.v19i3.1205

Introduction

Diabetic retinopathy (DR) is the most common ocular complication seen in patients with diabetes mellitus (DM).¹ Chronic hyperglycaemia is a major factor in the onset and progression of DR because of its tissue damaging effects.² Hyperglycemia activates alternative pathways of glucose metabolism which

include the polyol pathway with advanced glycation end products (AGEs) formation, protein kinase C (PKC) activation and hexosamine pathway flux and Poly(ADP-ribose) polymerase activation.³ These pathways lead to activation of cytokines and growth factors, leading to vascular endothelial dysfunction, increased vascular permeability, and eventual microvascular occlusion. Microvascular occlusion then leads to retinal ischemia, which promotes neovascularization and the formation of intraretinal vascular abnormalities.¹ Inflammatory cytokines are significantly up-regulated in diabetes, and as a result, chronic inflammation and endothelial damage lead to increased vascular permeability of blood vessels.⁴ These retinal changes would ultimately lead to blindness if vascular leakages result in diabetic macular oedema (DMO). Blindness could also occur when ischaemia-induced neovascularization results in vitreous haemorrhage, tractional retinal detachment or neovascular glaucoma or when capillary occlusion results in macular ischaemia or papillopathy.²

Diabetic retinopathy is the leading cause of blindness globally among adults aged 50 years and above, accounting for 0.9% of blindness among the same age group in Sub-Saharan Africa.⁵ It is a leading cause of blindness among the working-age group.⁶ This has a significant impact on the life of the affected individual, the individual's family, and society at large. This is regrettably so because blindness from DR is preventable. Early detection through screening and early treatment with follow-up goes a long way in preventing blindness from DR.^{7,8}

The global prevalence of diabetic retinopathy among diabetics was estimated at 27.0% between 2015 and 2018.⁹ Both clinic-based studies and population-based studies in parts of Africa have reported different prevalence rates for DR. The former reported a range of 7.0 – 62.4% in different clinics across Africa.¹⁰ Previous population-based studies in Egypt, and Kenya reported a prevalence of 17.9% and 35.9% respectively.^{11,12} A systematic review that determined the epidemiology of DR and Diabetic maculopathy in Africa between 1990 and 2011 reported a prevalence of 30.2–31.6% for DR, 0.9 – 1.3% for PDR and 1.2 – 4.5% for diabetic maculopathy.¹⁰

The prevalence of diabetes in Africa was 4.7% in the year 2015 and is projected to increase to 5.2% by the year 2045 in persons aged 20-79 years. Africa is also

known to have the highest proportion of undiagnosed diabetics (59.7%) in the world.¹³ In Nigeria, the pooled prevalence of diabetes in Nigeria was found to be 5.77%, with an estimated 11.2 million individuals (one out of every 17 adults) living with the disease.¹⁴ The National Blindness and Visual impairment survey reported that almost half (48.1%) of the people found with DM were not aware of the diagnosis.¹⁵ In the same survey, 20.5% of the diabetic population had DR. In the diabetic population, 10.8% had sight threatening PDR while 51.4% were found with macular oedema. Akaraiwe et al found a prevalence of 32.1% among diabetics at a DR screening centre in South-Eastern Nigeria.¹⁶ This prevalence was close to the prevalence of 36% found among diabetic patients attending a hospital on Northern Nigeria.¹⁷ The prevalence of DR and macular oedema in North-central Nigeria as found in a hospital-based study among diabetics in Jos Plateau state was 18.5% and 14.3% respectively.¹⁸ There are no published findings on the prevalence of DR in Benue state.

The International Clinical Diabetic Retinopathy Disease Severity Scale,¹⁹ classified DR based on clinical retinal findings into Non-proliferative DR (NPDR) and proliferative DR (PDR). It is classified as Mild NPDR when only microaneurysms are present, Moderate NPDR when more than just microaneurysms are present (but less than severe NPDR) and Severe NPDR when any one or more of severe haemorrhages in all 4 quadrants, significant venous beading in 2 or more quadrants, moderate IRMA in 1 or more quadrants - the 4-2-1 rule) is present. This carries a risk of PDR up to 50% within a year.

PDR is when one or more of, neovascularization, vitreous/pre-retinal haemorrhage or tractional retinal detachment occurs.¹⁹ Diabetic retinopathy usually progresses through these stages, ultimately resulting in vision loss without an intervention.

Diabetic macular oedema (DMO) can run an independent course and occur at any stage of retinopathy.²⁰ It is classified by the International Clinical Diabetic Macular Oedema Severity Scale as follows: Diabetic macular oedema absent (No retinal thickening or hard exudates in the posterior pole) and Diabetic macular oedema present (Some retinal thickening or hard exudates in the posterior pole). Vision-threatening DR (VTDR) is the stage of DR that would soon result in blindness if left untreated.

This includes severe NPDR, PDR, and DMO.²¹ Interventions and follow-up schedules for diabetic patients following DR screening, depend on the grade of DR identified on clinical examination of diabetics.²² Diabetic retinopathy screening which guarantees early detection and intervention for people living with DM has been shown to reduce the incidence of blindness from diabetic retinopathy.⁷ Various screening approaches and guidelines have been adopted by health systems across the world. The American Academy of Ophthalmology's (AAO) preferred practice pattern for DR recommends primary eye examinations for type 1 diabetics within 5 years after diagnosis, while type 2 diabetics should be screened at the time of diagnosis. Follow up should be yearly if no DR or mild NPDR is detected.²³ The national guideline for DR screening in Nigeria recommends screening patients with Type 1 DM annually, from 12 years of age and annually from diagnosis for patients with type 2 DM.²⁴ Risk factors for DR include duration of DM, Urban residence, overweight/obesity, lower high-density lipoprotein (HDL) cholesterol, and moderate triglyceride HDL cholesterol ratio.^{15,25} The purpose of this study was to determine the prevalence of diabetic retinopathy and clinical correlates of diabetic patients receiving care at the Benue State University Teaching Hospital Makurdi, following screening for DR. This will provide data for policy and interventions in Makurdi and its environs. It will be an advocacy tool that will encourage stakeholders to key into the national guidelines for diabetic retinopathy screening outlined by Nigeria's National Eye Health Program (NEHP).

Methods and materials

Study Area: The study was conducted in the General out patient department (GOPD), Endocrinology and Ophthalmology clinics, of the Benue State University Teaching Hospital (BSUTH), Makurdi, Benue State, Nigeria. The hospital is a tertiary care centre located in the state capital with a capacity of over 350 beds.

The GOPD attends to patients of different ages with varying health problems on an outpatient basis. The Endocrinology unit is a sub-specialty unit that caters to the needs of patients with endocrine system disorders, one of which is diabetes. The ophthalmology department offers general

ophthalmology care, with sub-specialty services in oculoplasty, glaucoma, and paediatric ophthalmology. The departments served as the main faculty for this study.

Study Population: This includes all consenting adult diabetic patients attending the endocrinology and general out-patient clinics at the BSUTH.

Inclusion and exclusion criteria: Those included in the study were clinically stable diabetics, 18 years and above. While those too sick (physically and mentally) or in-patients were excluded.

Study Design: This was an analytic cross-sectional, hospital-based study conducted within a eight months period from November 2020 to June 2021.

Sample size determination: A minimum sample size of 371 study participants was calculated (after accounting for 10% attrition) using the Leslie-Kish formula.²⁶ $n = Z^2 \times P(1-p)/D^2$. Where n = desired sample size, Z = The standard normal deviate set at 1.96, which corresponds to the 95% confidence level, p stands for the prevalence of 32.1% in an existing study, and d = degree of accuracy desired = 0.05 and Z = The standard normal deviate set at 1.96, which corresponds to the 95% confidence level

Sampling Technique: Diabetic patients were selected for the study as they attended the endocrinology clinic during the study period. Patients who gave their consent and met the inclusion criteria were included in the study through a systematic random sampling technique. The sampling frame was the register of patients with diabetes attending the general outpatient and endocrinology clinics. The first patient was selected by simple random sampling (balloting). Thereafter, a sampling interval of 2 was used to select subsequent participants. If for any reason, the patient to be selected declines or has already been sampled, the next patient in the sampling frame was selected. Systematic random sampling continued until the sample size was attained.

Study Instruments: A semi-structured interviewer-administered questionnaire was used for data collection. It was translated to native languages by translation specialists and then back-translated to English for consistency and to ensure the questions retained their original meaning. The questionnaire was divided into four sections: A to D which were biodata, past medical history, diabetic retinopathy awareness/ practices and clinical data (ocular and systemic examination data). The questionnaire was

developed and standardized by review of previous literature. Content validation was done by experienced supervisors.

Other materials used for the study include illuminated Snellen's visual acuity chart, weighing scale, stadiometer, mercury sphygmomanometer (for measuring blood pressure), slit-lamp biomicroscope (to examine the anterior segment of the eye), a Goldman applanation tonometer (to measure intraocular pressure - IOP), 0.5% amethocaine drops to anaesthetize the cornea for IOP and gonioscopy, a Goldman 2-mirror gonio lens with methyl cellulose as a coupling agent (to examine the anterior chamber angle), a binocular indirect ophthalmoscope (Welch Allyn 12500) (to examine the fundus of the eye), a 78D Volk lens was (to examine the optic disc and macula), 0.8% Tropicamide and 5% Phenylephrine combination (for pupillary dilation) and a Canon CR-2 plus AF digital fundal camera (to take fundal photographs for grading of DR).

Study Procedure: Each of the enrolled participants had their biodata and history captured on an interviewer-administered questionnaire in the appropriate language. A retrospective clinical record review was also carried out to clarify the patients' type (In this study, any diagnosis of DM before age 30 was classified as type 1 while a DM diagnosis after 30 years of age was classified as type 2),^{27,28} duration of DM, treatment and co-morbidities and to determine the average of each patient's fasting blood glucose (FBG) over the preceding 3 to 6 months. This was done by the principal researcher and research assistants.

The blood pressure and the anthropometric measurements (height, weight) were obtained, and the body mass index (BMI) was calculated using these parameters and classified as Underweight ($<18.5 \text{ Kg/m}^2$), Normal (18.5 to 24.9 Kg/m^2), Overweight (25 to 29.9 Kg/m^2) and Obese ($\geq 30 \text{ Kg/m}^2$).²⁹

Hypertension was regarded as an average systolic blood pressure of $\geq 140 \text{ mmHg}$, average diastolic blood pressure of $\geq 90 \text{ mmHg}$ or use of antihypertensive medication.³⁰

The presenting (unaided) and aided visual acuities (VA) were obtained in either eye using an illuminated Snellen's chart which was read at six meters (6M)

'External eye examination (lid and ocular adnexa, ocular alignment and extraocular motility) of each patient was done with a pen torch, and the findings

documented. Other examinations conducted using a slit lamp bio-microscope were anterior segment examination, IOP measurement, and gonioscopy with a Goldman 2- mirror gonio-lens, in a dimly lit room. Dilated funduscopy was carried out with the binocular indirect ophthalmoscope and 78D Volk lens'.

The participants then had their fundal photographs taken using a Canon CR-2 plus AF digital fundal camera. A 2-field (one centered on the disc and another centered on the macula) digital fundal photograph of the fundus was taken using the Canon CR-2 plus AF digital fundal camera with a 45° field of view.

The photographs were assessed by two independent graders by viewing 'full screen' images on a 21.5-inch monitor and a final interpretation recorded. In cases where there were conflicting interpretations, that senior ophthalmologist was recorded.

The presence or absence of DR was documented, and DR was graded if present. A patient was diagnosed as having DR if features of DR or DMO were noted in either eye. Features which included the presence of one or more of retinal microaneurysms, haemorrhages, exudates, cotton wool spots, venous beading, intraretinal vascular abnormalities, neovascularisation, macular oedema, tractional retinal detachment or vitreous haemorrhage.¹⁹ Diabetic retinopathy was classified into non-proliferative diabetic retinopathy (NPDR) which could be mild, moderate or severe or proliferative diabetic retinopathy (PDR) using the International Clinical Diabetic Retinopathy Disease and Macular Oedema Severity Scale classification of DR.³¹

The eye with the higher DR grade was used for analysis. Patients with Severe NPDR, PDR or clinically significant/ symptomatic macula oedema were referred for further specialised management.

Data management and analysis: The data obtained was entered and analysed using the International Business Machines (IBM) statistical package for social sciences (SPSS) version 23.

Independent variables such as age, gender, and sex were inputted, and descriptive analysis (mean and standard deviation for quantitative variables and frequencies and percentages for categorical variables) was done and presented as tables and charts. Bivariate analysis was carried out using chi-square for categorical variables to test the association between the outcome variable and independent

variables. Multivariate analysis (logistic regression) was then used to control confounders. A p-value < 0.05 was accepted as statistically significant.

Ethical consideration: The study adhered to the tenets of the Helsinki declaration.³² Ethical approval was obtained for the study from the Ethics and Research Committee of the hospital (BSUTH/CMAC/HREC/2020/008). Written informed consent was obtained from all participants. Participants were assured of strict confidentiality of information and their liberty to withdraw from the study at any time they did not feel comfortable to continue in the study.

Table 1: Sociodemographic Characteristics of Participants

Variable	Male		Female		Total	
	Frequency	Percent (%)	Frequency	Percent (%)	Frequency	Percent (%)
Age (years)						
<30	3	0.8	0	0.0	3	0.8
30 – 39	26	7.0	21	5.7	47	12.7
40 – 49	18	4.8	46	12.4	64	17.2
50 – 59	45	12.1	72	19.4	117	31.5
60 – 69	34	9.2	62	16.7	96	25.9
≥70	30	8.1	14	3.8	44	11.9
Total	156	42.0	215	58.0	371	100.0
Educational Status						
None	6	1.6	43	11.6	49	13.2
Primary	16	4.3	39	10.5	55	14.8
Secondary	37	10.0	45	12.1	82	22.1
Tertiary	97	26.1	88	23.8	185	49.9
Total	156	42.0	215	58.0	371	100.0

Table 2: Disease Characteristics of Participants

Variables	Frequency(n=371)	Percent (%)
Duration of Diabetes Mellitus (years)		
<5	106	28.6
5 – 9	121	32.6
10 – 14	60	16.2
15 – 19	51	13.7
≥20	33	8.9
Type of DM		
1	21	5.7
2	350	94.3
Type of Treatment		
Oral hypoglycaemics	306	82.5
Insulin	37	10.0
Insulin and Oral Hypoglycaemics	28	7.5
Co-existing Hypertension		
Yes	257	69.3
No	114	30.7
Fasting Plasma Glucose (mmol/L)		
<7.0	128	34.5
≥7.0	243	65.5
Co-existing renal disease		
Yes	63	17.0
No	308	83.0
Last HbA1c (mmol/L) (n=21)		
<7.0	3	14.3
≥7.0	18	85.7
Treatment of hyperlipidaemia		
Yes	51	13.7
No	320	86.3

Results

A total of 371 diabetic patients participated in the study. The mean age of the participants was 54.4 ± 11.6 years, with a range of 23 to 76 years. The male to female ratio (M: F) was 1:1.4. The majority 255

(68.7%) of the participants were of the Tiv ethnic group and about 185 (50%) had tertiary education. The median duration of DM was 9.0 years (interquartile range – 6.0). The mean FBS was 8.9 ± 3.3 mmol/L. There were 257 (69.3%) participants with co-existing hypertension and 63 (17.0%) with co-existing renal disease. Only 21 participants (5.7%) had documented HbA1C results.

Table 3: Systemic Examination Findings of Participants

Variable	Frequency(n=371)	Percent (%)
Systolic BP (mmHg)		
Normal	306	82.5
Elevated	65	17.5
Diastolic BP (mmHg)		
Normal	199	53.6
Elevated	172	46.4
BMI (kg/m²)		
Normal	49	13.2
Overweight	175	47.2
Obese	147	39.6

Most of the patients had controlled systolic (82.5%) and diastolic (53.6%) blood pressure while the majority of the patients were either overweight (47.2%) or obese (39.6%).

Table 4: Presenting Visual Acuity of Participants

Visual Acuity	Right Eye		Left Eye		
	Snellen (LogMAR)	Frequency	Percent (%)	Frequency	Percent (%)
6/5	-0.08	23	6.2	20	5.4
6/6	0.00	50	13.5	70	18.9
6/9	0.17	81	21.8	73	19.7
6/12	0.30	63	17.0	68	18.3
6/18	0.48	39	10.5	27	7.3
6/24	0.60	29	7.8	45	12.1
6/36	0.77	52	14.0	29	7.8
6/60	1.00	24	6.5	2	0.5
CF	2.00	4	1.1	8	2.2
HM	3.00	3	0.8	18	4.9
LP	5.00	3	0.8	11	3.0
Total		371	100.0	371	100.0
Mean (LogMAR)		0.44 ±0.59		0.46 ±0.63	

CF= counting fingers, HM= hand movement, LP= light perception



Figure 2: Proportion of Patients with Diabetic Retinopathy (DR)

Diabetic macular oedema was found in 64 (44.4%) of the patients with DR.

Ocular Examination

A total of 742 eyes of 371 patients were examined.

The proportion of patients with normal presenting visual acuity increased from 62.3% to 84.9% when aided with a pinhole.

Table 5: Ocular Abnormalities Detected (All Eyes) in Participants

Variable	Frequency	Percent (%)
Preseptal cellulitis	1	0.2
Ptosis	7	1.1
Stye	1	0.2
Xanthelasma Palpebrum	3	0.5
Pterygium	64	10.3
Iris Neovascularisation	3	0.5
Early Lens Opacity*	232	37.3
Cataract**	16	2.6
Aphakia	5	0.8
Asteroid hyalosis	2	0.3
Hypertensive retinopathy***	30	4.8
Glaucoma	110	17.7
Age Related Macular Degeneration	4	0.6
Diabetic Retinopathy/ macular oedema	144	23.1
Total	622	100.0

* lens opacity allowing visualisation of the fundus (WHO grading less than or equal to NUC 2, COR 2, PSC 1).³³

**Any lens opacity precluding visualisation of the fundus (WHO grading greater than NUC 2, COR 2, PSC 1).³⁴

***characterised by retinal arteriolar narrowing, arteriovenous nipping, or copper wiring in hypertensive patients.³⁴

Fundal examination could not be carried out in 16 eyes of 16 patients due to media opacities. 18 eyes were pseudophakic, 12 patients had early lens opacity (ELO) with pterygium (reported under pterygium) and 3 patients had ELO with Iris neovascularization (reported under iris neovascularization)

The presence of DR was significantly associated with DM duration, plasma glucose ≥ 7.0 mmol/L, uncontrolled systolic hypertension and renal disease ($p < 0.001$)




Figure 3: Distribution of Grades of Diabetic Retinopathy

Majority [89 (61.8%)] of patients with DR had mild NPDR

Table 6: Association between diabetic retinopathy and selected variables among Participants

Variable	Diabetic Retinopathy Yes(%)	No(%)	Total(%)	Chi-square	p-value
Duration of Diabetes Mellitus (years)				114.35	* <0.001
<5	9(8.5)	97(91.5)	106(100.0)		
5 - 9	34(28.1)	87(71.9)	121(100.0)		
10 - 14	34(56.7)	26(43.3)	60(100.0)		
15 - 19	40(78.4)	11(21.6)	51(100.0)		
≥ 20	27(81.8)	6(18.2)	33(100.0)		
Average Fasting Plasma Glucose (mmol/L)				13.98	* <0.001
<7.0	33(25.8)	95(74.2)	128(100.0)		
≥ 7.0	111(45.7)	132(54.3)	243(100.0)		
HBA1C (mmol/L)				0.509	0.586
<7.0	2(66.7)	1(33.3)	3(100.0)		
≥ 7.0	8(44.4)	10(55.6)	18(100.0)		
Systolic B.P (mmHg)				10.882	* 0.001
Normal	107(35.0)	199(65.0)	306(100.0)		
Elevated	37(56.9)	28(43.1)	65(100.0)		
Diastolic B.P (mmHg)				0.479	0.522
Normal	74(37.2)	125(62.8)	199(100.0)		
Elevated	70(40.7)	102(59.3)	172(100.0)		
Treatment for Hyperlipidaemia				0.061	0.806
Yes	19(37.2)	32(62.8)	51(100.0)		
No	125(31.9)	195(68.1)	320(100.0)		
Renal Disease				12.675	* <0.001
Yes	37(58.7)	26(41.3)	63(100.0)		
No	107(34.7)	201(65.3)	308(100.0)		

*Statistically significant

Table 7: Odd's Ratio and Logistic Regression of Significant Variables for Diabetic Retinopathy

Variable	AOR	95% Confidence Interval	p-value
Fasting Blood Sugar			
≥ 7.0	2.869	1.730 – 4.757	0.001*
<7.0	Reference		
Systolic BP (mmHg)			
Elevated	2.305	1.316 – 4.037	0.004*
Normal	Reference		
Renal Disease			
Yes	3.267	1.810 – 5.897	<0.001*
No	Reference		
Diabetes Duration (years)	1.286	1.221 – 1.354	<0.001*

AOR = Adjusted Odds ratio *statistically significant

For every additional year of diabetes duration, there was a 1.286 increase in the risk of diabetic retinopathy and this was statistically significant ($p < 0.001$).

Discussion

The mean age of the participants was 54.4 ± 11.6 years, with a range of 23 to 76 years. The mean age was similar to that in the studies in Nigeria by Nwosu et al (57.2 years), 35 Ashaye et al (57.5 ± 10.4 years)³⁶ and Lawan et al (52.14 ± 13.23 years).¹⁷ The mean age was lower than the mean found in the study by Kizor-Akaraiwe et al¹⁶ in which patients included in the study were those who came for eye screening after being invited from their diabetic clinics. These patients were more likely to be older patients who have ocular symptoms, as a large proportion of acquired eye diseases commonly occur with increasing age. There was a male to female ratio of 1:1.4 which is similar to that found in the study by Lawan et al,¹⁷ but at variance with other studies

within Nigeria.^{16,17} This may be because men were more likely to be at work during clinic hours when the study was carried out. Another possible reason may be that DM is likely to be unmasked during pregnancy resulting in more women being aware that they have DM.

More patients (94.3%) had Type 2 DM which is in keeping with both local and global trends.^{15,17,37}

Diabetic retinopathy was found in 144 (38.8%) of the patients examined. This is similar to findings in other hospital-based studies within Nigeria that reported DR rates of between 32.1 to 41%.^{15,16,17,38} This finding is, however, much higher than the prevalence of 15% reported by Omolase et al.¹⁹ This may be because they used direct ophthalmoscopy which is less sensitive than fundal photography which was used in this study, for the diagnosis of DR. Thus, some DR might have been missed.

The presence of DR was significantly associated with the duration of DM in this study (<0.001). There was a steady increase in the proportion of patients with DR as the duration of DM increased. Lawan et al²⁸ also found an association between DR and a duration of DM longer than 15 years. There was also an association between DM duration of 11 years or longer and DR in another Nigerian study.¹⁶ There was a 1.3 increase in the risk of diabetic retinopathy for every additional year of DM duration. This finding may be due to the prolonged and cumulative effect of risk factors. Voigt et al in their study of type 2 diabetic patients found that the prevalence of DR increased with increasing duration of DM. They proposed decreasing the frequency of DR screening among patients with well-controlled diabetes for less than ten years without complications from yearly to biennially.³⁹

Significant associations were also found between DR and poor glycaemic control with average FBS ≥ 7.0 mmol/L ($P < 0.001$), systolic hypertension ($P = 0.001$) and renal disease ($P < 0.001$). These associations were also found in other studies including randomised controlled clinical trials which showed that controlling these risk factors reduces the chances of developing DR and its progression.⁴⁰⁻⁴³ They have also been established as risk factors for the development of DR. A study by Saini et al among DR patients found that the presence and severity of diabetic retinopathy could predict the presence and severity of diabetic nephropathy.⁴⁴ Diabetic patients with systolic hypertension should be monitored

closely for the development of DR. The importance of blood pressure control and DR screening should be communicated clearly to such patients by their managing physicians. Only 21 participants had their HbA1c levels recorded. The association between DR and a high HbA1C was not significant in this study and is not in keeping with other studies.^{40,42} This may be because the proportion of patients with available HbA1C results was little and thus such inferences may be unreliable.

This study did not use HbA1C one of the clinical parameters. This is a limitation as HbA1C is a better predictor of glycaemic control than fasting blood sugar. However, this does not negate the important evidence generated and reported by this study.

Conclusion

The prevalence of DR was high, and occurrence of DR is found to be associated with a longer duration of diabetes mellitus, poor glycaemic control, systolic hypertension, and renal disease. Adequate control of blood glucose and comorbidities may significantly reduce the risk of developing diabetic retinopathy. Routine screening of diabetic patients (especially those with a longer history of DM) and early treatment of DR will reduce the risk of developing sight-threatening DR and blindness.

References

1. Diabetic retinopathy pathophysiology. EyeWiki [Internet]. [cited 2025 Jun 23]. Available from: https://eyewiki.org/Diabetic_Retinopathy_Pathophysiology
2. American Academy of Ophthalmology. Section 12: Retina and vitreous. San Francisco: American Academy of Ophthalmology; 2023. p. 102–150.
3. Wang W, Lo ACY. Diabetic retinopathy: pathophysiology and treatments. *Int J Mol Sci.* 2018;19(6):1816.
4. Rübsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy. *Int J Mol Sci.* 2018;19(4).
5. Bourne RRA, Steinmetz JD, Saylan M, Merasha AM, Weldemariam AH, Wondmeneh TG, et al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: The Right to Sight: an analysis for the Global Burden of Disease Study. *Lancet Glob Health.*

- 2021;9(2):e144–60.
6. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. *Lancet*. 2010;376(9735):124–36.
 7. Scanlon PH. The English National Screening Programme for diabetic retinopathy 2003–2016. *Acta Diabetol*. 2017;54(6):515–25.
 8. Stefánsson E, Bek T, Porta M, Larsen N, Kristinsson JK, Agardh E. Screening and prevention of diabetic blindness. *Acta Ophthalmol Scand*. 2000;78(4):374–85.
 9. Thomas RL, Halim S, Gurudas S, Sivaprasad S, Owens DR. IDF Diabetes Atlas: a review of studies utilising retinal photography on the global prevalence of diabetes-related retinopathy between 2015 and 2018. *Diabetes Res Clin Pract*. 2019;157:107840.
 10. Burgess PI, MacCormick IJC, Harding SP, Bastawrous A, Beare NAV, Garner P. Epidemiology of diabetic retinopathy and maculopathy in Africa: a systematic review. *Diabet Med*. 2013;30(4):399–412.
 11. AlSawahli H, Mpyet CD, Ezzelarab G, Hassanin I, Shalaby M, Safa O, et al. Population-based cross-sectional prevalence survey of diabetes and diabetic retinopathy in Sohag, Egypt, 2019. *BMJ Open*. 2021;11(6).
 12. Mathenge W, Bastawrous A, Peto T, Leung I, Yorston D, Foster A, et al. Prevalence and correlates of diabetic retinopathy in a population-based survey of older people in Nakuru, Kenya. *Ophthalmic Epidemiol*. 2014;21(3):169–77.
 13. Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. *Diabetes Res Clin Pract*. 2017;128:40–50.
 14. Uloko AE, Musa BM, Ramalan MA, Gezawa ID, Puepet FH, Uloko AT, et al. Prevalence and risk factors for diabetes mellitus in Nigeria: a systematic review and meta-analysis. *Diabetes Ther*. 2018;9(3):1307–16.
 15. Kyari F, Tafida A, Sivasubramaniam S, Murthy GV, Peto T, Gilbert CE. Prevalence and risk factors for diabetes and diabetic retinopathy: results from the Nigeria National Blindness and Visual Impairment Survey. *BMC Public Health*. 2014;14:1299.
 16. Kizor-Akaraiwe NN, Ezegwui IR, Oguego N, Uche NJ, Asimadu IN, Shiweobi J. Prevalence, awareness and determinants of diabetic retinopathy in a screening centre in Nigeria. *J Community Health*. 2016;41(4):767–71.
 17. Lawan A, Mohammed TB. Pattern of diabetic retinopathy in Kano, Nigeria. *Ann Afr Med*. 2012;11(2):75–9.
 18. Ewuga RO, Adenuga OO, Wade PD, Edah JO. Prevalence and risk factors for diabetic retinopathy in North-Central Nigeria. *Ghana Med J*. 2018;52(4):215.
 19. Wu L. Classification of diabetic retinopathy and diabetic macular edema. *World J Diabetes*. 2013;4(6):290.
 20. American Academy of Ophthalmology. International Clinical Diabetic Retinopathy Disease Severity Scale. San Francisco: American Academy of Ophthalmology; 2002.
 21. Zhang X, Saaddine JB, Chou CF, Cotch MF, Cheng YJ, Geiss LS, et al. Prevalence of diabetic retinopathy in the United States, 2005–2008. *JAMA*. 2010;304(6):649–56.
 22. Early Treatment Diabetic Retinopathy Study Research Group. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics: ETDRS report number 7. *Ophthalmology*. 1991;98(5):741–56.
 23. Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JJ, Vemulakonda GA, et al. Diabetic retinopathy Preferred Practice Pattern®. *Ophthalmology*. 2020;127(1):P66–145.
 24. Federal Ministry of Health and Social Welfare, Nigeria. National guidelines for screening and management of diabetic retinopathy. Abuja: Federal Ministry of Health and Social Welfare; 2023.
 25. Sahiledengle B, Assefa T, Negash W, Tahir A, Regasa T, Tekalegn Y, et al. Prevalence and factors associated with diabetic retinopathy among adult diabetes patients in Southeast Ethiopia: a hospital-based cross-sectional study. *Clin Ophthalmol*. 2022;16:3527–45.
 26. Bolarinwa OA. Sample size estimation for health and social science researchers: the principles and considerations for different study designs. *Niger Postgrad Med J*. 2018;27:19–26.
 27. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2010;33 Suppl 1:S62.
 28. Diaz-Valencia PA, Bougnères P, Valleron AJ. Global epidemiology of type 1 diabetes in young adults and adults: a systematic review. *BMC*

- Public Health. 2015;15(1):1–15.
29. Weir CB, Jan A. BMI classification percentile and cut off points. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021.
 30. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. *Circulation*. 2016;134(6):441–50.
 31. American Academy of Ophthalmology. International clinical classification of diabetic retinopathy: severity of diabetic macular edema. San Francisco: American Academy of Ophthalmology; 2002. p. 3–5.
 32. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA*. 2013;310(20):2191–4.
 33. Thylefors B, Chylack LT, Konyama K, Sasaki K, Sperduto R, Taylor HR, et al. A simplified cataract grading system. *Ophthalmic Epidemiol*. 2002;9(2):83–95.
 34. Salmon JF. Kanski's clinical ophthalmology: a systematic approach. 9th ed. London: Elsevier; 2020. p. 508–9.
 35. Nwosu SNN. Diabetic retinopathy in Nnewi, Nigeria. *Niger J Ophthalmol*. 2000;8(1):7–10.
 36. Ashaye A, Arije A, Kuti M, Olusanya B, Ayeni E, Fasanmade A, et al. Retinopathy among type 2 diabetic patients seen at a tertiary hospital in Nigeria: a preliminary report. *Clin Ophthalmol*. 2008;2(1):103.
 37. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract*. 2019;157:107843.
 38. World Health Organization. Prevention of blindness from diabetes mellitus: report of a WHO consultation in Geneva, Switzerland, 9–11 November 2005. Geneva: World Health Organization; 2006.
 39. Voigt M, Schmidt S, Lehmann T, Köhler B, Kloos C, Voigt U, et al. Prevalence and progression rate of diabetic retinopathy in type 2 diabetes patients in correlation with the duration of diabetes. *Exp Clin Endocrinol Diabetes*. 2018;126(9):570–6.
 40. Lima VC, Cavalieri GC, Lima MC, Nazario NO, Lima GC. Risk factors for diabetic retinopathy: a case-control study. *Int J Retina Vitreous*. 2016;2(1):21.
 41. Jee D, Lee WK, Kang S. Prevalence and risk factors for diabetic retinopathy: the Korea National Health and Nutrition Examination Survey 2008–2011. *Invest Ophthalmol Vis Sci*. 2013;54(10):6827–33.
 42. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med*. 1993;329(14):977–86.
 43. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ*. 1998;317(7160):703–13.
 44. Saini DC, Kochar A, Poonia R. Clinical correlation of diabetic retinopathy with nephropathy and neuropathy. *Indian J Ophthalmol* [Internet]. 2021 [cited 2025 Jul 18];69(11):3364–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/34708806/>
- i. Consent for publication** – All authors have read the manuscript and have approved it for publication
- ii. Availability of data and materials:** The datasets generated during and/or analysed during this study are available from the corresponding author on reasonable request.
- iii. Funding** - No external funding
- iv. Authors' contributions:**
Conception – T.J.B., K.C., U.A.E. Design of the work - T.J.B., M.B., U.A.E. Acquisition - T.J.B. Analysis - T.J.B., U.A.E. Interpretation of data - T.J.B., M.B., K.C. Draft - T.J.B., U.A.E. Revision - T.J.B., K.C., U.A.E.
- v. Acknowledgement:** The authors wish to acknowledge the management of Benue University Teaching Hospital, Makurdi, Nigeria for the approval of the study to be conducted in the general outpatient clinic of the hospital.